Why the study?
Pulmonary arterial hypertension in congenital heart disease increases morbidity and mortality, but current evaluation relies on invasive right heart catheterization.
Are plasma HGF and OPN potential biomarkers for pulmonary arterial hypertension in congenital heart disease?
Observational (n=68)
No
Are plasma HGF and OPN potential biomarkers for pulmonary arterial hypertension in congenital heart disease?
Plasma HGF and OPN are being investigated as potential non-invasive biomarkers for pulmonary arterial hypertension in congenital heart disease.
May support biomarker research in PAH-CHD; leaves open clinical utility pending prospective validation.
Objectives: Pulmonary arterial hypertension in congenital heart disease (PAH-CHD) is the most common type of PAH and increases morbidity and mortality in patients with CHD. Right heart catheterization (RHC) is the standard me... | Find, read and cite all the research you need on Tech Science Press
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2021) conducted an observational in Pulmonary arterial hypertension in congenital heart disease (n=68). Plasma HGF, OPN, and ST2 levels vs. Healthy controls and CHD patients without PAH was evaluated on Diagnostic efficacy of HGF for PAH-CHD (AUC 0.692, p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: